Nu Skin Enterprises, Inc. (NUS) AI Stock Analysis

Nu Skin Enterprises, Inc. is a global company in the beauty and wellness industry, focused on developing and distributing skincare systems and nutritional supplements. Founded in 1984 and headquartered in Provo, Utah, the company markets products under brands such as Nu Skin, Pharmanex, and ageLOC. Its offerings include ageLOC Spa and ageLOC Transformation skincare systems, the ageLOC LumiSpa cleansing device, and nutritional supplements like LifePak, ageLOC Youth, ageLOC Meta, and Beauty Focus Collagen+. The company operates retail stores and service centers, particularly in Mainland China, and distributes products worldwide through direct selling, distributors, and online channels.

Nu Skin reported annual revenue of $1.49B in FY2025, down 14.3% from $1.73B in FY2024 and $2.70B in FY2021. Gross margin stood at 69.4% in FY2025, while operating margin recovered to 6.1% compared to -8.8% in FY2024. Net income reached $160.2M in FY2025 with an EPS of $3.20, following a net loss of -$146.6M in FY2024. For the trailing twelve months ending June 30, 2026, revenue stood at $1.38B with an operating margin of 6.1% and a net margin of -15.7%. In the latest quarter, revenue fell 17.1% year-over-year, while quarterly earnings dropped 98.2%.

As of June 30, 2026, Nu Skin held $189.6M in cash and short-term investments against total debt of $263.7M, resulting in net debt of $74.1M. The company had a current ratio of 1.98, total assets of $1.12B, and shareholders' equity of $542.7M, reflecting a debt-to-equity ratio of 0.49. In FY2025, operating cash flow was $80.3M and free cash flow was $46.0M. During that fiscal year, cash deployment included $34.3M in capital expenditures, $20.0M in share buybacks, and $11.8M in dividend payments.

At a last close of $5.14, Nu Skin holds a market capitalization of $250.2M and an enterprise value of $296.8M. The company trades at a forward P/E of 4.0x, a price-to-sales ratio of 0.2x, and an EV-to-EBITDA of 7.5x. These multiples are below the median of its US-listed Consumer Defensive peers, which post a forward P/E of 14.3x, price-to-sales of 0.7x, and EV-to-EBITDA of 11.7x. Over the past year, Nu Skin stock fell 50.0%, compared to a 16.8% return for the S&P 500 (SPY). Over five years, the stock dropped 85.0% while the benchmark rose 83.0%.

Nu Skin offers a forward annual dividend of $0.24 per share, providing a dividend yield of 4.67% with a payout ratio of 24.7%. The dividend is distributed quarterly, and the company has paid dividends for 26 consecutive years. However, its 5-year annualized dividend growth is -30.7%. The last ex-dividend date occurred on August 28, 2026.

Wall Street coverage includes a mean price target of $12.77, representing a 148.4% difference from the last close of $5.14. For the fiscal year ending December 31, 2026, analysts estimate revenue of $1.32B and an EPS of $0.82, which indicates an EPS decline of 35.4%. For the next fiscal year, 1 analyst projects revenue of $1.47B and EPS of $1.16. Nu Skin beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of Nu Skin Enterprises, Inc. (NUS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NUS income statement, NUS balance sheet, NUS key metrics, NUS analyst forecast, NUS chart. See the NUS stock overview for the latest quote and news.